These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 14991194)

  • 41. Clinical pharmacology of levosimendan.
    Antila S; Sundberg S; Lehtonen LA
    Clin Pharmacokinet; 2007; 46(7):535-52. PubMed ID: 17596101
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Levosimendan].
    Michels G; Herzig S; Hoppe UC
    Dtsch Med Wochenschr; 2005 Oct; 130(43):2444-6. PubMed ID: 16240243
    [No Abstract]   [Full Text] [Related]  

  • 43. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
    Earl GL; Fitzpatrick JT
    Ann Pharmacother; 2005 Nov; 39(11):1888-96. PubMed ID: 16219899
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Levosimendan: current status and future prospects.
    Archan S; Toller W
    Curr Opin Anaesthesiol; 2008 Feb; 21(1):78-84. PubMed ID: 18195615
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Levosimendan for heart-operated patients: what is the state of the art?
    Tagarakis GI; Tsilimingas NB
    Recent Pat Cardiovasc Drug Discov; 2009 Jan; 4(1):22-4. PubMed ID: 19149702
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The prolonged lowering effect of levosimendan on brain natriuretic peptide levels in patients with decompansated heart failure: clinical implications.
    Celik T; Iyisoy A; Yuksel UC; Kardesoglu E
    Int J Cardiol; 2008 Aug; 128(1):97-9; authr reply 100-2. PubMed ID: 18501448
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan.
    Antila S; Kivikko M; Lehtonen L; Eha J; Heikkilä A; Pohjanjousi P; Pentikäinen PJ
    Br J Clin Pharmacol; 2004 Apr; 57(4):412-5. PubMed ID: 15025738
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study.
    Husebye T; Eritsland J; Müller C; Sandvik L; Arnesen H; Seljeflot I; Mangschau A; Bjørnerheim R; Andersen GØ
    Eur J Heart Fail; 2013 May; 15(5):565-72. PubMed ID: 23288914
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The vasoactive-inotropic score and levosimendan: time for LVIS?
    Favia I; Vitale V; Ricci Z
    J Cardiothorac Vasc Anesth; 2013 Apr; 27(2):e15-6. PubMed ID: 23507021
    [No Abstract]   [Full Text] [Related]  

  • 50. Efficacy of levosimendan in patients with chronic heart failure: Does rhythm matter?
    Yontar OC; Yilmaz MB; Yalta K; Tandoğan I
    Anadolu Kardiyol Derg; 2010 Aug; 10(4):310-6. PubMed ID: 20693125
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessment of sustained effects of levosimendan on right ventricular systolic functions in patients with advanced heart failure.
    Mansiroglu AK; Oner E; Erturk M; Karakurt H; Somuncu MU; Birant A; Kalkan AK; Ozturk D; Eksik A
    Acta Cardiol; 2016 Aug; 71(4):411-5. PubMed ID: 27594356
    [No Abstract]   [Full Text] [Related]  

  • 52. Cost-effectiveness of levosimendan in patients with acute heart failure.
    Fedele F; D'Ambrosi A; Bruno N; Caira C; Brasolin B; Mancone M
    J Cardiovasc Pharmacol; 2011 Oct; 58(4):363-6. PubMed ID: 21697728
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of levosimendan in patients with acute right heart failure: A meta-analysis.
    Qiu J; Jia L; Hao Y; Huang S; Ma Y; Li X; Wang M; Mao Y
    Life Sci; 2017 Sep; 184():30-36. PubMed ID: 28689804
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Experience with levosimendan in 32 paediatric patients.
    Vilaboa Pedrosa C; Martínez Roca C; Yáñez Gómez P; Martín Herranz MI
    Pediatr Cardiol; 2015 Jun; 36(5):1038-41. PubMed ID: 25608697
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of Levosimendan on Patients with Heart Failure Complicating Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled Trials.
    Shang G; Yang X; Song D; Ti Y; Shang Y; Wang Z; Tang M; Zhang Y; Zhang W; Zhong M
    Am J Cardiovasc Drugs; 2017 Dec; 17(6):453-463. PubMed ID: 28597399
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure.
    Lilleberg J; Laine M; Palkama T; Kivikko M; Pohjanjousi P; Kupari M
    Eur J Heart Fail; 2007 Jan; 9(1):75-82. PubMed ID: 16829185
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Levosimendan: a retrospective single-center case series.
    Berry WT; Hewson RW; Langrish CJ; McKenzie CA; Barrett NA
    J Crit Care; 2013 Dec; 28(6):1075-8. PubMed ID: 23998721
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure.
    Sandell EP; Hayha M; Antila S; Heikkinen P; Ottoila P; Lehtonen LA; Pentikainen PJ
    J Cardiovasc Pharmacol; 1995; 26 Suppl 1():S57-62. PubMed ID: 8907132
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Value of IGF-I levels in the evaluation of response to treatment with levosimendan in patients with severe heart failure.
    Işık S; Cetin M; Ciçekçioğlu H; Uçar O; Çetin ZG; Ozuğuz U; Bakır F; Berker D; Güler S
    Anadolu Kardiyol Derg; 2011 Sep; 11(6):523-9. PubMed ID: 21821501
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacologic treatment of heart failure due to ventricular dysfunction by myocardial stunning: potential role of levosimendan.
    García González MJ; Domínguez Rodríguez A
    Am J Cardiovasc Drugs; 2006; 6(2):69-75. PubMed ID: 16555860
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.